v3.26.3
SEGMENT INFORMATION (Tables)
 9 Months Ended
Sep. 30, 2026
Segment Reporting [Abstract]  
Schedule of segment revenues and profit
Segment revenues and profits for the three and nine months ended September 30, 2026 and 2025 were as follows:
Vision CarePharmaceuticalsSurgicalTotal
Three Months Ended September 30,
(in millions)20262025202620252026202520262025
Revenues
Product Sales$773 $734 $366 $329 $232 $214 $1,371 $1,277 
Other Revenues1 2 1 1 2 1 4 4 
774 736 367 330 234 215 1,375 1,281 
Expenses
Cost of goods sold (excluding amortization and impairments of intangible assets)281 279 88 106 116 124 
Cost of other revenues— — 1 1 — — 
Selling, general and administrative240 225 127 132 77 72 
Research and development9 15 17 15 9 11 
Segment Profit$244 $217 $134 $76 $32 $8 410 301 
Corporate(168)(153)
Amortization of intangible assets(57)(68)
Other (expense) income, net(30)15 
Operating income155 95 
Interest income2 3 
Interest expense(95)(101)
Loss on extinguishment of debt— 3 
Foreign exchange and other (4)(3)
Income (loss) before provision for income taxes$58 $(3)
Vision CarePharmaceuticalsSurgicalTotal
Nine Months Ended September 30,
(in millions)20262025202620252026202520262025
Revenues
Product Sales$2,262 $2,139 $1,024 $902 $713 $641 $3,999 $3,682 
Other Revenues7 6 2 4 5 4 14 14 
2,269 2,145 1,026 906 718 645 4,013 3,696 
Expenses
Cost of goods sold (excluding amortization and impairments of intangible assets)843 820 255 303 396 390 
Cost of other revenues— — 2 4 — — 
Selling, general and administrative715 689 414 439 230 218 
Research and development36 34 66 36 34 34 
Segment Profit$675 $602 $289 $124 $58 $3 1,022 729 
Corporate(499)(497)
Amortization of intangible assets(171)(202)
Other expense, net(81)(29)
Operating income271 1 
Interest income10 9 
Interest expense(285)(323)
Loss on extinguishment of debt(1)(6)
Foreign exchange and other (12)(11)
Loss before provision for income taxes$(17)$(330)
Schedule of revenues by segment and product category
Revenues by segment and product category were as follows:
Vision CarePharmaceuticalsSurgicalTotal
Three Months Ended September 30,
(in millions)20262025202620252026202520262025
Pharmaceuticals$1 $1 $318 $279 $— $— $319 $280 
Devices285 270 — — 232 214 517 484 
OTC477 454 — — — — 477 454 
Branded and Other Generics10 9 48 50 — — 58 59 
Other revenues1 2 1 1 2 1 4 4 
$774 $736 $367 $330 $234 $215 $1,375 $1,281 
Nine Months Ended September 30,
20262025202620252026202520262025
Pharmaceuticals$3 $3 $882 $759 $— $— $885 $762 
Devices808 763 — — 713 641 1,521 1,404 
OTC1,418 1,344 — — — — 1,418 1,344 
Branded and Other Generics33 29 142 143 — — 175 172 
Other revenues7 6 2 4 5 4 14 14 
$2,269 $2,145 $1,026 $906 $718 $645 $4,013 $3,696